90Y-IDEC-159 (90Y-huCC49ΔCH2) is an anti-TAG-72 antibody labeled with 90Y and being developed by Biogen Idec. It is being developed for the treatment of colon cancer, as a back-up for 131I- and 177Lu-labeled CC49.
CC49, a monoclonal antibody reactive to tumor-associated glycoprotein (TAG-72), has been extensively studied for radioimmunotherapy for colon cancer in the form of 131I-CC49 and 177Lu-CC49. Tumor response in Phase I/II trials was not conclusive. Myelotoxicity has been dose-limiting because of prolonged circulation time in the plasma, and human anti-mouse antibody responses were observed in the majority of patients. IDEC-159 is a CH2 domain deleted and humanized CC49 (huCC49ΔCH2) which was developed to ameliorate these problems and the radiolabeled drug was tested in colon cancer patients.
A Phase I/II trial in colorectal cancer patients was performed between 2005 and 2010 with both 111In-IDEC-159 and 90Y-IDEC-159. Safety studies have shown that doses up to 0.5 mCi/kg were associated with reversible myelotoxicity, but the drug showed high hepatotoxicity which needed to be reduced. No new trial has been started since 2010.